Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.58 |
| ▸ | KIF11 | P52732 | 12/20 | 0.56 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL764696 | 0.92 | MAPT (0.61) | LMNAKIF11ABCG2TP53 | |
| SCHEMBL8402724 | 0.90 | KIF11 (0.55) | LMNAKIF11ABCG2TP53POLB | |
| SCHEMBL13646748 | 0.90 | LMNA (0.53) | LMNAKIF11ABCG2TP53POLB | |
| SCHEMBL4923677 | 0.90 | LMNA (0.58) | LMNAKIF11ABCG2TP53 | |
| SCHEMBL4929832 | 0.90 | LMNA (0.58) | LMNAKIF11ABCG2TP53POLB | |
| SCHEMBL763967 | 0.89 | LMNA (0.58) | LMNAKIF11ABCG2TP53POLB | |
| SCHEMBL763417 | 0.88 | KIF11 (0.60) | LMNAKIF11ABCG2TP53 | |
| SCHEMBL764045 | 0.88 | LMNA (0.51) | LMNAKIF11ABCG2TP53POLB | |
| SCHEMBL764779 | 0.88 | LMNA (0.52) | LMNAKIF11ABCG2TP53POLB | |
| SCHEMBL11912437 | 0.87 | LMNA (0.51) | LMNAKIF11ABCG2TP53POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080103164-A1 | USEFUL COMPOUNDS FOR HPV INFECTION | SMITHKLINE BEECHAM CORPORATION | 2008-05-01 | — | — | US | claimed |
| EP-1786425-A1 | USEFUL COMPOUNDS FOR HPV INFECTION | SmithKline Beecham Corporation (US) | 2007-05-23 | — | — | EP | claimed |
| WO-2007002051-A1 | CARBOLINE DERIVATIVES AND THEIR USE AS INHIBITORS OF FLAVIVIRIDAE INFECTIONS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-01-04 | — | — | WO | claimed |
| WO-2006015035-A1 | USEFUL COMPOUNDS FOR HPV INFECTION | SMITHKLINE BEECHAM CORPORATION (US) | 2006-02-09 | — | — | WO | claimed |
| US-20240043422-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS, INC. (US) | 2024-02-08 | — | — | US | disclosed |
| US-11613538-B2 | Method of inhibiting or reducing a viral infection | PTC THERAPEUTICS, INC. (US) | 2023-03-28 | — | — | US | disclosed |
| EP-2434891-B9 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS INC (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20200317668-A1 | METHOD OF INHIBITING OR REDUCING A CORONAVIRIDAE VIRUS INFECTION | PTC THERAPEUTICS, INC. | 2020-10-08 | — | — | US | disclosed |
| EP-3718405-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC Therapeutics, Inc. (US) | 2020-10-07 | — | — | EP | disclosed |
| EP-2434891-B1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS INC (US) | 2020-07-22 | — | — | EP | disclosed |
| US-20190194188-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20160340354-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS, INC. | 2016-11-24 | — | — | US | disclosed |
| US-20120157400-A1 | METHODS FOR TREATING KAPOSI SARCOMA | PTC THERAPEUTICS, INC. | 2012-06-21 | — | — | US | disclosed |
| US-20120157401-A1 | METHODS FOR TREATING NEUROFIBROMATOSIS | PTC THERAPEUTICS, INC. | 2012-06-21 | — | — | US | disclosed |
| US-20080103164-A1 | USEFUL COMPOUNDS FOR HPV INFECTION | SMITHKLINE BEECHAM CORPORATION | 2008-05-01 | — | — | US | disclosed |
| US-20080103164-A1 | USEFUL COMPOUNDS FOR HPV INFECTION | SMITHKLINE BEECHAM CORPORATION | 2008-05-01 | — | — | US | disclosed |
| US-20080103164-A1 | USEFUL COMPOUNDS FOR HPV INFECTION | SMITHKLINE BEECHAM CORPORATION | 2008-05-01 | — | — | US | disclosed |
| EP-1786425-A1 | USEFUL COMPOUNDS FOR HPV INFECTION | SmithKline Beecham Corporation (US) | 2007-05-23 | — | — | EP | disclosed |
| WO-2007002051-A1 | CARBOLINE DERIVATIVES AND THEIR USE AS INHIBITORS OF FLAVIVIRIDAE INFECTIONS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2006015035-A1 | USEFUL COMPOUNDS FOR HPV INFECTION | SMITHKLINE BEECHAM CORPORATION (US) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043422-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | HDGF, POLRMT, VEGFA | LMNA 1839/4885KIF11 2547/4885ABCG2 4203/4885 |
| US-20160340354-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | HDGF, POLRMT, VEGFA | LMNA 1803/4885KIF11 2569/4885ABCG2 4199/4885 |
| US-20190194188-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | HDGF, POLRMT, VEGFA | LMNA 1803/4885KIF11 2569/4885ABCG2 4199/4885 |
| US-20200317668-A1 | METHOD OF INHIBITING OR REDUCING A CORONAVIRIDAE VIRUS INFECTION | SARS1, POLRMT, EIF2AK2 | LMNA 2784/4885KIF11 3683/4885ABCG2 4052/4885 |
| US-20120157401-A1 | METHODS FOR TREATING NEUROFIBROMATOSIS | VHL, NGF, VEGFA | LMNA 1622/4885KIF11 1626/4885ABCG2 4681/4885 |
| US-11613538-B2 | Method of inhibiting or reducing a viral infection | SARS1, EIF2AK2, POLRMT | LMNA 2454/4885KIF11 3731/4885ABCG2 4104/4885 |
| US-20080103164-A1 | USEFUL COMPOUNDS FOR HPV INFECTION | TP53, POLI, PCNA | LMNA 2288/4885KIF11 3280/4885ABCG2 2793/4885 |
| US-20120157400-A1 | METHODS FOR TREATING KAPOSI SARCOMA | HDGF, HIF1AN, VEGFA | LMNA 1893/4885KIF11 1065/4885ABCG2 3539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.